| Description | BV-2 Cells Derivation and biomarker
BV-2 is a type of microglial cell derived from C57/BL6 murine. The BV2 cells are immortalized by v-raf/v-myc carrying J2 retrovirus. BV2 express nuclear v-myc and the cytoplasmic v-raf oncogene products as well as the env gp70 antigen at the surface level. BV2 microglia cell line retains microglia morphological and functional characteristics. In accordance with v-raf/v-myc expressed characters, the metabolic and proliferation rate of in vitro BV-2 greatly exceeds that of other microglia. Why Choose BV-2 from AcceGen?
AcceGen BV-2 cells are positive for MAC1 and MAC2 antigens, negative for MAC3, glial fibrillary acidic protein (GFAP) and galactocerebroside (GC). |
| Citation Guide | When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
Hagan, N., Kane, J.L., Grover, D., Woodworth, L., Madore, C., Saleh, J., Sancho, J., Liu, J., Li, Y., Proto, J. and Zelic, M., 2020. CSF1R signaling is a regulator of pathogenesis in progressive MS. Cell death & disease, 11(10), pp.1-25. |
| Application | For research use only
BV-2 Cells Application and example model
In the central nervous systems (CNS), microglial cells are resident macrophages. BV-2 shares properties with body macrophages with respect to the antigen profile, their phagocytic capacity and antimicrobial activity. Like other microglia, BV-2 can be activated to release pro-inflammatory cytokines by oxidative stress or inflammatory factors. Such stimulus possibly triggers neurodegenerative disorder such as Alzheimer and Parkinson disease, thus BV-2 is widely used as an alternative model system for primary microglia and neurodegenerative disease model in vitro. The model is usually induced by Lipopolysaccharide (LPS) treatment. |
